CTOR revenueQ3 2026$1.49M
- QoQ
- -10.4%
CTOR revenue was $1.49M in fiscal Q3 2026 (ended Jun 30, 2026), down 10.4% from the prior quarter.
Citius Oncology Inc. (CTOR) financials
For the twelve months ended Jun 30, 2026, Citius Oncology Inc. reported -$46.06M of net income.
- Net income, TTM
- -$46.06M
- EPS, diluted, TTM
- -$0.47
- Cash
- $16.56M
- Market cap
- $52.0M
FY2024FY2025
CTOR revenue and earnings growth
CTOR net incomeQ3 2026-$8.92M
CTOR net income was -$8.92M in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$5.37M a year earlier. For the full fiscal 2025 it was -$24.76M, compared with -$21.15M in fiscal 2024.
CTOR EPSQ3 2026-$0.08
CTOR diluted EPS was -$0.08 in fiscal Q3 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.34, compared with -$0.31 in fiscal 2024.
Income statement
| Line item | Sep 30, 2025 | Sep 30, 2024 |
|---|---|---|
| Research and development | $6.42M | $4.93M |
| Selling, general and admin | $8.78M | $8.15M |
| Operating income | -$23.52M | -$20.57M |
| Interest expense | $218.0K | - |
| Pre-tax income | -$23.70M | -$20.57M |
| Income tax | $1.06M | $576.0K |
| Net income | -$24.76M | -$21.15M |
| EPS, basic | -$0.34 | -$0.31 |
| EPS, diluted | -$0.34 | -$0.31 |
| Diluted shares | 73.3M | 68.1M |
Balance sheet
| Line item | Sep 30, 2025 | Sep 30, 2024 |
|---|---|---|
| Cash and equivalents | $3.92M | $112 |
| Inventory | $22.29M | $8.27M |
| Current assets | $27.54M | $10.97M |
| Total assets | $100.94M | $84.37M |
| Current liabilities | $49.49M | $32.70M |
| Total liabilities | $56.08M | $38.23M |
| Shareholders' equity | $44.87M | $46.14M |
Cash flow
| Line item | Sep 30, 2025 | Sep 30, 2024 |
|---|---|---|
| Operating cash flow | -$5.49M | $126.4K |
| Investing cash flow | -$5.75M | -$5.00M |
| Financing cash flow | $15.17M | $4.87M |
| Stock-based compensation | $8.32M | $7.50M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49M | $1.67M | $3.94M | - | - | - | - | - | - | - | - |
| Cost of revenue | $491.8K | $328.9K | $789.2K | - | - | - | - | - | - | - | - |
| Gross profit | $1.00M | $1.34M | $3.15M | - | - | - | - | - | - | - | - |
| Research and development | $218.5K | $1.08M | $1.02M | $1.08M | $938.3K | $3.14M | $1.26M | $1.30M | $1.13M | $1.35M | $1.15M |
| Selling, general and admin | $4.22M | $23.63M | $2.86M | $1.34M | $1.88M | $2.24M | $3.32M | $3.71M | $1.54M | $1.39M | $1.52M |
| Operating income | -$8.72M | -$28.61M | -$5.25M | -$4.71M | -$4.94M | -$7.47M | -$6.39M | -$6.67M | -$4.63M | -$268.4K | - |
| Interest expense | $231.7K | $33.0K | $45.8K | $57.3K | $160.8K | - | - | - | - | - | - |
| Pre-tax income | -$9.03M | -$26.84M | -$5.27M | -$4.73M | -$5.11M | -$7.47M | -$6.39M | -$6.67M | -$4.63M | -$4.69M | -$4.58M |
| Income tax | -$107.3K | -$231.2K | $264.2K | $264.2K | $264.2K | $264.2K | $264.2K | $144.0K | $144.0K | $144.0K | $144.0K |
| Net income | -$8.92M | -$26.61M | -$5.53M | -$5.00M | -$5.37M | -$7.74M | -$6.66M | -$6.81M | -$4.77M | -$4.84M | -$4.73M |
| EPS, basic | -$0.08 | -$0.27 | -$0.06 | -$0.06 | -$0.08 | -$0.11 | -$0.09 | -$0.10 | -$0.07 | -$0.07 | -$0.07 |
| EPS, diluted | -$0.08 | -$0.27 | -$0.06 | -$0.06 | -$0.08 | -$0.11 | -$0.09 | -$0.10 | -$0.07 | -$0.07 | -$0.07 |
| Diluted shares | 107.9M | 100.0M | 87.5M | - | 71.6M | 71.6M | 71.6M | - | 67.5M | 67.5M | 67.5M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $16.56M | $2.63M | $7.30M | $3.92M | $112 | $112 | $112 | $112 | $261 | $33.3K | $32.7K |
| Receivables | $686.2K | $1.08M | $4.05M | - | - | - | - | - | - | - | - |
| Inventory | $22.63M | $22.66M | $22.64M | $22.29M | $17.21M | $15.34M | $14.38M | $8.27M | - | - | - |
| Current assets | $42.71M | $29.42M | $37.15M | $27.54M | $18.31M | $18.04M | $17.08M | $10.97M | $41.0K | $94.4K | $58.2K |
| Total assets | $112.09M | $100.70M | $109.97M | $100.94M | $91.71M | $91.44M | $90.48M | $84.37M | $49.19M | $48.68M | $72.62M |
| Current liabilities | $58.79M | $58.81M | $44.71M | $49.49M | $52.99M | $49.74M | $43.40M | $32.70M | $3.08M | $2.82M | $2.05M |
| Total liabilities | $71.71M | $65.43M | $51.56M | $56.08M | $59.31M | $55.80M | $49.19M | $38.23M | - | - | - |
| Shareholders' equity | $40.38M | $35.27M | $58.41M | $44.87M | $32.40M | $35.64M | $41.29M | $46.14M | $17.03M | $19.85M | $22.73M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.71M | -$3.83M | -$7.35M | - | - | - | - | - | - | -$191.7K | - |
| Investing cash flow | -$2.00M | -$600.0K | -$4.40M | - | - | - | - | - | - | $24.74M | - |
| Financing cash flow | $18.64M | -$231.2K | $15.13M | - | - | - | - | - | - | -$24.55M | - |
| Stock-based compensation | $3.56M | $3.53M | $3.96M | $2.30M | $2.13M | $2.09M | $1.81M | $1.67M | $1.96M | $1.96M | $1.92M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 67.1% | 80.3% | 80.0% | - | - | - | - | - | - | - | - |
| Operating margin | -583.5% | -1716.2% | -133.2% | - | - | - | - | - | - | - | - |
| Net margin | -597.4% | -1596.0% | -140.3% | - | - | - | - | - | - | - | - |
| Current ratio | 0.73 | 0.50 | 0.83 | 0.56 | 0.35 | 0.36 | 0.39 | 0.34 | 0.01 | 0.03 | 0.03 |
Source: XBRL data Citius Oncology Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CTOR peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CTOR | - | - | -$46.06M | - | $52.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
CTOR FAQ
5 questionsIs CTOR profitable?
No. Citius Oncology Inc. reported a net loss of $46.06M for the twelve months ended Jun 30, 2026.How much cash and debt does CTOR have?
Citius Oncology Inc. reported $16.56M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CTOR earnings per share?
Diluted earnings per share were -$0.47 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did CTOR last report financial results?
The latest statements here come from Citius Oncology Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this CTOR financial data come from?
Quantisnow builds these statements from the structured XBRL data Citius Oncology Inc. files with the SEC. It is provided for information only and is not investment advice.